RESTON, Va., Oct. 7, 2024 /PRNewswire/ — Leidos (NYSE: LDOS), a Fortune 500® innovation leader, was recently awarded a $303 million contract to oversee planning, analysis, and operations for the Department of the Air Force’s (DAF) Advanced Battle Management System – Digital Infrastructure (ABMS-DI) network, which is a core component of the DAF Battle Network. The contract was awarded by the DAF Program Executive Officer Command, Control, Communications and Battle Management and covers a three-year performance period, with two option years.

“For battle managers to make faster and better-informed decisions, they need government and commercial technologies to work together seamlessly,” said Roy Stevens, Leidos National Security Sector President. “We will lead the secure, rapid integration of cloud computing, data analytics, and communications capabilities so that our Airmen and Guardians have the tactical, operational, and strategic data they need.”

As ABMS-DI network manager, Leidos will perform a wide range of management functions to support the successful standup of the Digital Infrastructure Network.

This contract extends Leidos’ collaborative role with the DAF to design, develop, and deploy modern combined Joint All-Domain Command and Control capabilities for the Air Force and Space Force.

About Leidos

Leidos is a Fortune 500® innovation company rapidly addressing the world’s most vexing challenges in national security and health. The company’s global workforce of 48,000 collaborates to create smarter technology solutions for customers in heavily regulated industries. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. For more information, visit www.leidos.com. 

Certain statements in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the fiscal year ended December 29, 2023, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made.

Media Contacts:

Alyssa Pettus
(571) 526-6743
alyssa.t.pettus@leidos.com

Greg Hellman
(571) 526-7592
greg.hellman@leidos.com

Brandon Ver Velde
(571) 526-6257
brandon.p.vervelde@leidos.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/department-of-air-force-selects-leidos-to-oversee-its-advanced-battle-management-system—digital-infrastructure-network-302268244.html

SOURCE Leidos Holdings, Inc.

NEW YORK and OORDEGEM, Belgium, Oct. 7, 2024 /PRNewswire/ — Life sciences industry veterans, Mario Philips and Roel Gordijn, today announced the launch of Enovo Life Sciences (“Enovo”), in partnership with Warburg Pincus, a leading global growth investor. Enovo will focus on identifying and acquiring one or more companies to build a market-leading life sciences platform serving the biologics and advanced therapies end markets. Enovo is backed by Warburg Pincus, which is currently investing out of its latest $17.3 billion global flagship fund, Warburg Pincus Global Growth 14 (“WP GG 14”).

Enovo is led by Mario Philips and his longtime colleague, Roel Gordijn. Mr. Philips and Mr. Gordijn collectively have over 50 years of leadership experience in the life sciences sector, including in vaccine and antibody manufacturing and, more recently, in the rapidly growing field of Advanced Therapy Medicinal Products. They played key roles in Warburg Pincus’ investment in Polyplus, a leading provider of upstream solutions for cell and gene therapies, where they oversaw significant organic growth and strategic acquisitions until its ultimate €2.4 billion sale to Sartorius Stedim Biotech last year.

Prior to his role as CEO of Polyplus, Mr. Philips, based in Belgium, held executive positions at Danaher/Pall Biotech, a leading life sciences company, and ATMI Life Sciences, a global technology company and leader in single-use bioprocessing solutions. Prior to his role as Chief Commercial Officer at Polyplus, Mr. Gordijn, based in the Netherlands, held a variety of executive roles at Danaher/Pall Biotech, ATMI Life Sciences, and Lonza.

Mario Philips, CEO, said, “Enovo Life Sciences will focus on acquiring one or more companies with proven capabilities and compelling growth potential with the aim of building a scaled, market-leading life sciences business. This platform will provide companies with the capital necessary to enable innovation that meets the needs of customers and patients, with the support of Warburg Pincus and its global network. We are well-positioned to invest in and develop a sizable platform where the latest technology and a sharp focus on value creation can unlock further growth.”

Roel Gordijn added, “We are thrilled at the prospect of building Enovo Life Sciences and continuing the success story we’ve had previously with Warburg Pincus. This investment will allow us to pursue partnerships with businesses with truly differentiated offerings and expertise. We are excited to partner with companies across the U.S., Europe and beyond, that are leaders in their respective fields.”

“The launch of this platform underscores our commitment to working with management teams and companies that support the delivery of innovative life sciences products and services worldwide. We strongly believe in the immense opportunity and the impact that biologics and advanced therapies can have on patients,” said T. J. Carella, Managing Director, Head of Healthcare, Warburg Pincus. “Mario and Roel have an unparalleled track record of leading and growing global businesses in life sciences and are the ideal executives to launch and build a platform that supports the development and delivery of life-changing therapies,” added Ruoxi Chen, Managing Director, Warburg Pincus.

Enovo will be supported by Warburg Pincus teams in London, New York and other global offices. The launch of Enovo follows Warburg Pincus’ announcement of Jake Strauss leading the healthcare investing practice in Europe, highlighting the firm’s commitment to healthcare investing at a global scale.

Since inception, Warburg Pincus has invested over $18 billion in more than 180 healthcare companies, including Summit Health, Modernizing Medicine, Ensemble Healthcare Partners, and Global Healthcare Exchange, and has been an active investor in life sciences, with investments in Norstella, PolyPlus, Simtra, Sotera Health, and Bausch + Lomb, among others.

About Warburg Pincus

Warburg Pincus LLC is a leading global growth investor. The firm has more than $83 billion in assets under management. The firm’s active portfolio of more than 225 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Since its founding in 1966, Warburg Pincus has invested more than $117 billion in over 1,000 companies globally across its private equity, real estate, and capital solutions strategies. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information, please visit www.warburgpincus.com. Follow us on LinkedIn.

Contact

info@enovolifesciences.com

View original content:https://www.prnewswire.com/news-releases/senior-life-sciences-executives-launch-enovo-life-sciences-in-partnership-with-warburg-pincus-302268756.html

SOURCE Enovo Life Sciences

Experienced Wealth Management Leader Joins from Ameriprise to Enhance Realta’s Recruiting Strategy

WILMINGTON, Del., Oct. 7, 2024 /PRNewswire/ — Realta Wealth, an exclusive independent wealth management firm, today announced Paul Tyler has joined as Senior Vice President, Director of Business Development. Reporting directly to CEO Kevin Keefe, Tyler will spearhead national recruiting efforts for the firm that will focus on recruiting accomplished financial professionals currently affiliated with the largest independent platforms in the industry seeking affiliation with a firm offering a true boutique culture and bespoke service model.

“As Realta continues to enhance its offerings to advisors, it’s important that we are actively out in the marketplace telling our story,” Keefe said. “Paul has the experience and talent to take our recruiting efforts to the next level. His track record of recruiting success and in-depth and current knowledge of the needs and wants of the type of elite advisors we are looking to attract, make him the perfect choice for this critical position.”

Tyler will be responsible for implementing a firm-wide strategy to enhance the nationwide recruiting of financial advisors to Realta. He will lead the Business Development team and be integral in the full recruitment cycle, from building a pipeline to coordinating Home Office visits to closing agreements with new advisors.

Before joining Realta, Tyler was a Regional Director, Experienced Advisor Recruiting at Ameriprise Financial Services. He held various positions at Ameriprise since starting there in 2007 as a financial advisor.

Tyler said, “Realta is a firm on the move, and I am thrilled to be here at this inflection point for our industry. With large independent broker-dealers giving up their cultures for the sake of building scale, many advisors want to make a change. Realta is committed to becoming the destination of choice for accomplished advisors on the move who want the personal connections and exceptional service experience of a partner investing in their future and sees them as much more than just another rep code.”

About Realta Wealth

Realta Wealth is an independent broker-dealer and RIA platform that enables financial professionals to maximize the success of their practices. Realta Wealth includes Realta Equities, Inc., a FINRA-registered independent broker-dealer, and Realta Investment Advisors, Inc., an SEC Registered Investment Advisor. Realta’s mission is to empower independent advisors to attract and serve affluent and high-net-worth clients. The firm provides advisors with best-in-class resources, bespoke support, a curated community of like-minded peers and a team of experienced and accessible executive leadership. The name Realta reflects the firm’s position as a guiding light committed to helping its advisors and clients reach their financial goals. Learn more at www.RealtaWealth.com.

Media Contacts
Haven Tower Group
Lorene Yue or Brandon Blackwell
424 317 4854 or 424 317 4868
lyue@haventower.com or bblackwell@haventower.com

View original content:https://www.prnewswire.com/news-releases/realta-wealth-names-paul-tyler-as-senior-vice-president-director-of-business-development-302268639.html

SOURCE Realta Wealth